Memantine in the treatment of mild-to-moderate Alzheimer’s disease

Bibliography

• HEBERT LE, SCHERR PA, BIENIAS JL et al.: Alzheimer’s disease in the US population. Arch. Neurol. (2003) 60(8):1119-1122.
   PubMed Web of Science ®Google Scholar
• BROOKMEYER R, GRAY S, KAWAS C: Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health (1998) 88(9):1337-1342.
   PubMed Web of Science ®Google Scholar
• EBLY EM, PARHAD IM, HOGAN DB, FUNG TS: Prevalence and types of dementia in the very old: results from the Canadian study of health and aging. Neurology (1994) 44(9):1593-1600.
   PubMed Web of Science ®Google Scholar
• KUKULL WA, HIGDON R, BOWEN JD et al.: Dementia and Alzheimer’s disease Incidence. Arch. Neurol. (2002) 59(11):1737-1746.
   PubMed Web of Science ®Google Scholar
• FLEISHER AS, HOUSTON WS, EYLER ET et al.: Identification of Alzheimer’s disease risk by functional magnetic resonance imaging. Arch. Neurol . (2005) 62(12):1881-1888.
   PubMedGoogle Scholar
• MORTIMER JA, BORENSTEIN AR, GOSCHE KM, SNOWDON DA: Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression. J. Geriatr. Psychiatry Neurol. (2005) 18(4):218-223.
   PubMed Web of Science ®Google Scholar
• MASDEU JC, ZUBIETA JL, ARBIZU J: Neuroimaging as a marker of the onset and progression of Alzheimer’s disease. J. Neurol. Sci. (2005) 236(1-2):55-64.
   PubMed Web of Science ®Google Scholar
• CUMMINGS JL, COLE G: Alzheimer’s disease. JAMA (2002) 87(18):2335-2338.
   Google Scholar
• RILEY KP, SNOWDON DA, MARKESBERY WR: Alzheimer’s neurofibrillatory pathology and the spectrum of cognitive function: findings from the Nun Study. Ann. Neurol. (2002) 51(5):567-577.
   PubMed Web of Science ®Google Scholar
• GREENAMYRE JT, MARAGOS WF, ALBIN RL, PENNEY JB, YOUNG AB: Glutamate transmission and toxicity in Alzheimer’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry (1988) 12(4):421-430.
   PubMed Web of Science ®Google Scholar
• DANYSZ W, PARSONS CG: The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence. Int. J. Geriatr. Psychiatry (2003) 18(Suppl. 1):S23-S32.
   PubMed Web of Science ®Google Scholar
• ROTHMAN SM, THURSTON JH, HAUHART RE: Delayed neurotoxicity of excitatory amino acids in vitro. Neuroscience (1987) 22(2):471-480.
   PubMed Web of Science ®Google Scholar
• VELLIQUETTE RA, O’CONNOR T, VASSAR, R: Energy inhibition elevates β-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer’s disease pathogenesis. J. Neurosci. (2005) 25(47):10874-10883.
   PubMed Web of Science ®Google Scholar
• SINDOU P, LESORT M, COURATIER P, YARDIN C, ESCLAIRE F, HUGON J: Glutamate increases tau phosphorylation in primary neuronal cultures from fetal rat cerebral cortex. Brain Res. (1994) 646(1):124-128.
   PubMed Web of Science ®Google Scholar
• COURATIER P, LESORT M, SINDOU P, ESCLAIRE F, YARDIN C, HUGON J: Modifications of neuronal phosphorylated tau immunoreactivity induced by NMDA toxicity. Mol. Chem. Neuropathol. (1996) 27(3):259-273.
   PubMedGoogle Scholar
• SCORZIELLO A, MEUCCI O, FLORIO T et al.: β25-35 Alters calcium homeostasis and induces neurotoxicity in cerebellar granule cells. J. Neurochem. (1996) 66(5):1995-2003.
   PubMed Web of Science ®Google Scholar
• MATTSON MP, CHENG B, DAVIS D, BRYANT K, LIEBERBURG I, RYDEL RE: β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. (1992) 12(2):376-389.
   PubMed Web of Science ®Google Scholar
• CUMMINGS JL: Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am. J. Geriatr. Psychiatry (2003) 11(2):131-145.
   PubMed Web of Science ®Google Scholar
• WATKINS PB, ZIMMERMAN HJ, KNAPP MJ, GRACON SI, LEWIS KW: Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA (1997) 271(13):992-998.
   Google Scholar
• GRACON SI, KNAPP MJ, BERGHOFF WG et al.: Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis. Assoc. Disord. (1998) 12(2):93-101.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER LS, TARIOT PN: Cognitive enhancers and treatments for Alzheimer’s disease. In: Psychiatry, 2nd edn. Tasman A, Kay J, Lieberman JA (Eds.) John Wiley and Sons, London, UK (2003):2096-2108.
   Google Scholar
• CUMMINGS JL: Alzheimer’s disease. N. Engl. J. Med. (2004) 351(1):56-67.
   PubMed Web of Science ®Google Scholar
• DOODY RS, STEVENS JC, BECK C et al.: Practice parameter: management of dementia (an evidence-based review). Neurology (2001) 56(9):1154-1166.
   PubMed Web of Science ®Google Scholar
• WINBLA DB, JELIC V: Long-term treatment of Alzheimer’s disease: efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Dis. Assoc. Disord. (2004) 18(Suppl. 1):S2-S8.
   Google Scholar
• SCHNEIDER LS, DAGERMAN K, INSEL PS: Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am. J. Geriatr. Psychiatry (2006) 14(3):191-210.
   PubMed Web of Science ®Google Scholar
• WANG PS, SCHNEEWEISS S, AVORN J et al.: Risk of death in elderly users of conventional versus atypical antipsychotic medications. N. Engl. J. Med. (2005) 353(22):2335-2341.
   PubMed Web of Science ®Google Scholar
• LYKETSOS CG, OLIN J: Depression in Alzheimer’s disease: overview and treatment. Biol. Psychiatry (2002) 52(3):243-252.
   PubMed Web of Science ®Google Scholar
• SCHENK D, BARBOUR R, DUNN W et al.: Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400(6740):173-177.
   PubMed Web of Science ®Google Scholar
• GAMES D, BARD F, GRAJEDA H et al.: Prevention and reduction of AD-type pathology in PDAPP mice immunized with Aβ 1-42. Ann. N. Y. Acad. Sci. (2000) 920:274-284.
   PubMed Web of Science ®Google Scholar
• GILMAN S, KOLLER M, BLACK RS et al.: Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 64(9):1553-1562.
   PubMed Web of Science ®Google Scholar
• ORGOGOZO JM, GILMAN S, DARTIGUES JF et al.: Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology (2003) 61(1):46-54.
   PubMed Web of Science ®Google Scholar
• SIGURDSSON EM, SCHOLTZOVA H, MEHTA PD, FRANGIONE B, WISNIEWSKI T: Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer’s disease-associated pathology in transgenic mice. Am. J. Pathol. (2001) 159(2):439-447.
   PubMed Web of Science ®Google Scholar
• BARD F, CANNON C, BARBOUR R et al.: Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer’s disease. Nat. Med. (2000) 6(8):916-919.
   PubMed Web of Science ®Google Scholar
• VASSAR R: β-secretase (BACE) as a drug target for Alzheimer’s disease. Adv. Drug. Deliv. Rev. (2002) 54(12):1589-1602.
   PubMed Web of Science ®Google Scholar
• TOMITA T, IWATSUBO T: γ-secretase as a therapeutic target for treatment of Alzheimer’s disease. Curr. Pharm. Des. (2006) 12(6):661-670.
   PubMed Web of Science ®Google Scholar
• ECKERT GP, WOOD WG, MÜLLER WE: Statins: drugs for Alzheimer’s disease? J. Neural. Transm. (2005) 112(8):1057-1071.
   PubMed Web of Science ®Google Scholar
• VEKRELLIS K, YE Z, QIU WQ et al.: Neurons regulate extracellular levels of amyloid β-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. (2000) 20(5):1657-1665.
   PubMed Web of Science ®Google Scholar
• BEHL C, MOOSMANN B: Oxidative nerve cell death in Alzheimer’s disease and stroke: antioxidants as neuroprotective compounds. Biol. Chem. (2002) 383(3-4):521-536.
   PubMed Web of Science ®Google Scholar
• STUCHBURY G, MUNCH G: Alzheimer’s associated inflammation, potential targets and future therapies. J. Neural Transm. (2005) 112(3):429-453.
   PubMed Web of Science ®Google Scholar
• ALVAREZ G, MUNOZ-MONTANO JR, SATRUSTEGUI J, AVILA J, BOGONEZ E, DIAZ-NIDO J: Regulation of tau phosphorylation and protection against β-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer’s disease. Bipolar Disord. (2002) 4(3):153-165.
   PubMed Web of Science ®Google Scholar
• TARIOT PN, LOY R, RYAN JM, PORSTEINSSON A, ISMAIL S: Mood stabilizers in Alzheimer’s disease: symptomatic and neuroprotective rationales. Adv. Drug. Deliv. Rev. (2002) 54(12):1567-1577.
   PubMed Web of Science ®Google Scholar
• TARIOT PN, FEDEROFF HJ: Current treatment for Alzheimer’s disease and future prospects. Alzheimer Dis. Assoc. Disord. (2003) 17(Suppl. 4):S105-S113.
   PubMed Web of Science ®Google Scholar
• WINBLAD B, MÖBIUS HJ, STÖFFLER A: Glutamate receptors as a target for Alzheimer’s disease-are clinical results supporting the hope? J. Neural. Transm. Suppl. (2002) 62:217-225.
   Google Scholar
• PARSONS CG, DANYSZ W, QUACK G: Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology (1999) 38(6):735-767.
   PubMed Web of Science ®Google Scholar
• DISTERHOFT JF, WU WW, OHNO M: Biophysical alterations of hippocampal pyramidal neurons in learning, ageing and Alzheimer’s disease. Ageing Research Reviews (2004) 3(4):383-406.
   PubMed Web of Science ®Google Scholar
• PROCTER A: Abnormalities in non-cholinergic neurotransmitter systems in Alzheimer’s disease. In: Dementia, 2nd edn. O’Brien J, Ames D, Burns A (Eds.) Oxford University Press, US (2000):433-442.
   Google Scholar
• LIPTON SA: Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Disc. (2006) 5(2):160-170.
   PubMed Web of Science ®Google Scholar
• DANYSZ W, PARSONS CG, KORNHUBER J, SCHMIDT WJ, QUACK G: Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci. Biobehav. Rev (1997) 21(4):455-468.
   PubMed Web of Science ®Google Scholar
• DANYSZ W, PARSONS CG, MÖBIUS HJ, STÖFFLER A, QUACK G: Neuroprotective and symptomalogical action of memantine relevant for Alzheimer’s disease – a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Res. (2000) 2:85-98.
   PubMed Web of Science ®Google Scholar
• MINKEVICIENE R, BANERJEE P, TANILA H: Memantine improves spatial learning in a transgenic mouse model of Alzheimer’s disease. J. Pharmacol. Exp. Ther. (2004) 311(2):677-682.
   PubMed Web of Science ®Google Scholar
• REISBERG B, DOODY R, STÖFFLER A, SCHMITT F, FERRIS S, MÖBIUS HJ: Memantine in moderate-to-severe Alzheimer’s disease. N. Engl. J. Med. (2003) 348(14):1333-1341.
   PubMed Web of Science ®Google Scholar
• REISBERG B, DOODY R, STÖFFLER A, SCHMITT F, FERRIS S, MÖBIUS HJ: A 24-week open-label extension study of memantine in moderate to sever Alzheimer’s disease. Arch. Neurol. (2006) 63(1):49-54.
   PubMed Web of Science ®Google Scholar
• TARIOT PN, FARLOW MR, GROSSBERG GT, GRAHAM SM, MCDONALD S, GERGEL I: Memantine treatment in patients with moderate to severe Alzheimer’s disease already receiving donepezil. JAMA (2004) 291(3):317-324.
   PubMed Web of Science ®Google Scholar
• WINBLAD B, PORITIS N: Memantine in severe dementia: results of the M-BEST study (Benefit and Efficacy in Severely Demented Patients during Treatment with Memantine). Int. J. Geriatr. Psychiatry (1999) 14(2):135-146.
   PubMed Web of Science ®Google Scholar
• ORGOGOZO JM, RIGAUD AS, STÖFFLER A, MÖBIUS HJ, FORETTE F: Efficacy and safety of memantine in patients with mild to moderate vascular dementia. Stroke (2002) 33(7):1834-1839.
   PubMed Web of Science ®Google Scholar
• WILCOCK G, MÖBIUS HJ, STÖFFLER A: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia. Int. Clin. Psychopharmacol. (2002) 17(6):297-305.
   PubMed Web of Science ®Google Scholar
• PESKINDER, POTKIN SG, POMARA N et al.: Memantine treatment in mild to moderate Alzheimer’s disease: a 24-week randomized controlled trial. Am. J. Geriatr. Psychiatry (2006) 14(8):704-715.
   Google Scholar
• MCSHANE R, AREOSA SA, MINAKARAN N: Memantine for dementia. Cochrane Database of Systematic Reviews (2006) (2):CD003154.
   Google Scholar
• PERICLOU A, VENTURA D, SHERMAN T et al.: A pharmacokinetic study of the NMDA receptor antagonist memantine and donepezil in healthy young subjects (abstract). J. Am. Geriatr. Soc. (2003) 51(Suppl. 4):S225.
   Google Scholar
• WENK= GL, QUACK G, MOEBIUS HJ, DANYSZ W: No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci. (2000) 66(12):1079-1083.
   PubMed Web of Science ®Google Scholar
• HARTMANN= S, MÖBIUS HJ: Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int. Clin. Psychopharmacol. (2003) 18(2):81-85.
   PubMed Web of Science ®Google Scholar
• PERICLOU AP, VENTURA D, SHERMAN T, RAO N, ABRAMOWITZ WT: Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann. Pharmacother. (2004) 38(9):1389-1394.
   PubMed Web of Science ®Google Scholar
• PERICLOU A, VENTURA D, RAO N, ABRAMOWITZ W: Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin. Pharmacol. Ther. (2006) 79(1):134-143.
   PubMed Web of Science ®Google Scholar